会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 82. 发明授权
    • Substituted oximes, hydrazones and olefins as neurokinin antagonists
    • 取代的肟,腙和烯烃作为神经激肽拮抗剂
    • US5945428A
    • 1999-08-31
    • US960724
    • 1997-10-30
    • Neng-Yang ShihGregory A. ReichardRobert G. Aslanian
    • Neng-Yang ShihGregory A. ReichardRobert G. Aslanian
    • C07D471/10A61K31/44C07D221/00
    • C07D471/10
    • Compound represented by the structural formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or 3;b, d and e are independently 0, 1 or 2;R is H, C.sub.1-6 alkyl, --OH or C.sub.2 -C.sub.6 hydroxyalkyl;A is an optionally substituted oxime, hydrazone or olefin;X is a bond, --C(O)--, --O--, --NR.sup.6 --, --S(O).sub.e --, --N(R.sup.6)C(O)--, --C(O)N(R.sup.6)-- --OC(O)NR.sup.6 --, --OC(.dbd.S)NR.sup.6 --, --N(R.sup.6)C(.dbd.S)O--, --C(.dbd.NOR.sup.1)--, --S(O).sub.2 N(R.sup.6)--, --N(R.sup.6)S(O).sub.2 --, --N(R.sup.6)C(O)O-- or --OC(O)--;T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl;Q is --SR.sup.6, --N(R.sup.6)(R.sup.7), --OR.sup.6, phenyl, naphthyl or heteroaryl;R.sup.6a, R.sup.7a, R.sup.8a, R.sup.9a, R.sup.6 and R.sup.7 are H, C.sub.1-6 alkyl, C.sub.2 -C.sub.6 hydroxyalkyl, C.sub.1 -C.sub.6 alkoxy-C.sub.1 -C.sub.6 alkyl, phenyl or benzyl; or R.sup.6 and R.sup.7, together with the nitrogen to which they are attached, form a ring;R.sup.9a is R.sup.6 or --OR.sup.6 ; andZ is spiro-substituted piperidinyl or substituted piperazinyl wherein aryl, heterocycloalkyl, heteroaryl, cycloalkyl and bridged cycloalkyl groups are optionally substituted; methods of treating asthma, cough, bronchospasm, imflammatory diseases, and gastrointestinal disorders with said compounds, and pharmaceutical compositions comprising said compounds are disclosed.
    • 由结构式表示的化合物或其药学上可接受的盐,其中:a为0,1,2或3; b,d和e独立地为0,1或2; R为H,C 1-6烷基,-OH或C 2 -C 6羟基烷基; A是任选取代的肟,腙或烯烃; X是键,-C(O) - , - O - , - NR 6 - , - S(O)e - , - N(R 6)C(O) - , - OC(O)NR6-, - OC(= S)NR6-,-N(R6)C(= S)O-,-C(= NOR1) - , - S(O) (R 6)S(O)2 - , - N(R 6)C(O)O-或-OC(O) - ; T是H,苯偶酰亚氨基,芳基,杂环烷基,杂芳基,环烷基或桥连环烷基; Q是-SR 6,-N(R 6)(R 7),-OR 6,苯基,萘基或杂芳基; R6a,R7a,R8a,R9a,R6和R7是H,C1-6烷基,C2-C6羟基烷基,C1-C6烷氧基-C1-C6烷基,苯基或苄基; 或R 6和R 7与它们所连接的氮一起形成环; R9a为R6或-OR6; Z是螺取代的哌啶基或取代的哌嗪基,其中芳基,杂环烷基,杂芳基,环烷基和桥连的环烷基任选被取代; 公开了用所述化合物治疗哮喘,咳嗽,支气管痉挛,炎性疾病和胃肠道疾病的方法,以及包含所述化合物的药物组合物。
    • 83. 发明授权
    • Imidazoylalkyl substituted with a six membered nitrogen containing
nitrogen containing heterocyclic ring
    • 用含六价氮的含氮杂环取代的咪唑烷基
    • US5932596A
    • 1999-08-03
    • US457352
    • 1995-06-01
    • Neng-Yang ShihMichael J. Green
    • Neng-Yang ShihMichael J. Green
    • C07D401/06A61K31/445
    • C07D401/06
    • Disclosed is a compound of Formula 1.0: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula 1.0.Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula 1.0 to a patient in need of such treatment.
    • 公开了式1.0的化合物或其药学上可接受的盐或溶剂化物。 还公开了包含药学上可接受的载体和有效量的式1.0化合物的药物组合物。 进一步公开的是治疗过敏(例如哮喘),炎症,高血压,升高的眼内压(例如青光眼)的方法,降低眼内压的方法,睡眠障碍,超低运动性和酸性分泌的状态 胃肠道,中枢神经系统的低血压和多动症(例如,激动和抑郁)和其他CNS疾病(例如阿尔茨海默病,精神分裂症和偏头痛),包括向有需要的患者施用有效量的式1.0化合物 这样的治疗。
    • 89. 发明授权
    • Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity
    • 具有CXCR3拮抗活性的杂环取代哌嗪化合物
    • US07902199B2
    • 2011-03-08
    • US11776901
    • 2007-07-12
    • Stuart B. RosenblumJoseph A. KozlowskiNeng-Yang ShihBrian F. McGuinnessDouglas W. Hobbs
    • Stuart B. RosenblumJoseph A. KozlowskiNeng-Yang ShihBrian F. McGuinnessDouglas W. Hobbs
    • A61K31/496C07D401/12C07D401/14
    • C07D401/14
    • The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g., tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    • 本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐,溶剂合物或酯的化合物或对映异构体,立体异构体,旋转异构体,互变异构体或前药,所述化合物具有式1所示的一般结构 :或其药学上可接受的盐,溶剂合物或酯。 还公开了治疗趋化因子介导的疾病的方法,例如姑息治疗,疗效治疗,某些疾病和疾病如炎性疾病的预防性治疗(非限制性实例,牛皮癣),自身免疫性疾病(非限制性的 例如,类风湿性关节炎,多发性硬化),移植物排斥(非限制性实例,包括同种异体移植排斥,移植排斥),感染性疾病(例如结核性麻风病),固定药物喷发,皮肤迟发型超敏反应 应答,眼部炎症,I型糖尿病,病毒性脑膜炎和使用式1的化合物的肿瘤。